


Highlights of This Issue 5571

SPECIAL FEATURES


CCR Translations

- 5573** Promising Cell-Based Immunotherapy Using Gamma Delta T Cells: Together Is Better
Julie Déchanet-Merville
See related articles, p. 5708 and p. 5720
- 5576** Perfect ALKemy: Optimizing the Use of ALK-Directed Therapies in Lung Cancer
Katerina Politi and Scott Gettinger
See related article, p. 5686

Molecular Pathways

- 5579** Molecular Pathways: IL11 as a Tumor-Promoting Cytokine—Translational Implications for Cancers
 Matthias Ernst and Tracy L. Putoczki

CCR Focus

- 5590** Central Nervous System Malignancies: What Next?
Susan E. Bates
- 5591** Facing the Future of Brain Tumor Clinical Research
Mark R. Gilbert, Terri S. Armstrong, Whitney B. Pope, Martin J. van den Bent, and Patrick Y. Wen
- 5601** The Evolving Role of Molecular Markers in the Diagnosis and Management of Diffuse Glioma
Jason T. Huse and Kenneth D. Aldape
- 5612** Antiangiogenic Therapy for Glioblastoma: Current Status and Future Prospects
Tracy T. Batchelor, David A. Reardon, John F. de Groot, Wolfgang Wick, and Michael Weller
- 5620** Immunotherapy for Primary Brain Tumors: No Longer a Matter of Privilege
 Peter E. Fecci, Amy B. Heimberger, and John H. Sampson

- 5630** Molecular Insights into Pediatric Brain Tumors Have the Potential to Transform Therapy
Amar Gajjar, Stefan M. Pfister, Michael D. Taylor, and Richard J. Gilbertson

CANCER THERAPY: CLINICAL

- 5641** Phase II Study of Perifosine and Sorafenib Dual-Targeted Therapy in Patients with Relapsed or Refractory Lymphoproliferative Diseases
Anna Guidetti, Carmelo Carlo-Stella, Silvia L. Locatelli, Walter Malorni, Roberta Mortarini, Simonetta Viviani, Domenico Russo, Alfonso Marchianò, Roberto Sorasio, Anna Dodero, Lucia Farina, Laura Giordano, Massimo Di Nicola, Andrea Anichini, Paolo Corradini, and Alessandro M. Gianni
- 5652** Phase I Trial of Bortezomib (PS-341; NSC 681239) and “Nonhybrid” (Bolus) Infusion Schedule of Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory Indolent B-cell Neoplasms
Beata Holkova, Maciej Kmiecik, E. Brent Perkins, Prithviraj Bose, Rachid C. Baz, G. David Roodman, Robert K. Stuart, Viswanathan Ramakrishnan, Wen Wan, Cody J. Peer, Jana Dawson, Loveleen Kang, Connie Honeycutt, Mary Beth Tombes, Ellen Shrader, Caryn Weir-Wiggins, Martha Wellons, Heidi Sankala, Kevin T. Hogan, A. Dimitrios Colevas, L. Austin Doyle, William D. Figg, Domenico Coppola, John D. Roberts, Daniel Sullivan, and Steven Grant
- 5663** Dose–Response Relationship in Phase I Clinical Trials: A European Drug Development Network (EDDN) Collaboration Study
Victor Moreno García, David Olmos, Carlos Gomez-Roca, Philippe A. Cassier, Rafael Morales-Barrera, Gianluca Del Conte, Elisa Gallerani, Andre T. Brunetto, Patrick Schöffski, Silvia Marsoni, Jan H.M. Schellens, Nicolas Penel, Emile Voest, Jeffrey Evans, Ruth Plummer, Richard H. Wilson, Jean Charles Soria, Josep Tabernero, Jaap Verweij, and Stan B. Kaye

Table of Contents

- 5672** **Interrogating Two Schedules of the AKT Inhibitor MK-2206 in Patients with Advanced Solid Tumors Incorporating Novel Pharmacodynamic and Functional Imaging Biomarkers**
Timothy A. Yap, Li Yan, Amita Patnaik, Nina Tunariu, Andrea Biondo, Ivy Fearan, Kyriakos P. Papadopoulos, David Olmos, Richard Baird, Liliana Delgado, Ernestina Tetteh, Robert A. Beckman, Lisa Lupinacci, Ruth Riisnaes, Shaun Decordova, Simon P. Heaton, Karen Swales, Nandita M. deSouza, Martin O. Leach, Michelle D. Garrett, Daniel M. Sullivan, Johann S. de Bono, and Anthony W. Tolcher

PERSONALIZED MEDICINE AND IMAGING


- 5686** **Two Novel ALK Mutations Mediate Acquired Resistance to the Next-Generation ALK Inhibitor Alectinib**
Ryohei Katayama, Luc Friboulet, Sumie Koike, Elizabeth L. Lockerman, Tahsin M. Khan, Justin F. Gainor, A. John Iafrate, Kengo Takeuchi, Makoto Taiji, Yasushi Okuno, Naoya Fujita, Jeffrey A. Engelman, and Alice T. Shaw
See related commentary, p. 5576
- 5697** **Serum Interleukin-8 Reflects Tumor Burden and Treatment Response across Malignancies of Multiple Tissue Origins**
Miguel F. Sanmamed, Omar Carranza-Rua, Carlos Alfaro, Carmen Oñate, Salvador Martín-Algarra, Guiomar Perez, Sara F. Landazuri, Álvaro Gonzalez, Stefanie Gross, Inmaculada Rodriguez, Cecilia Muñoz-Calleja, María Rodríguez-Ruiz, Bruno Sangro, José M. López-Picazo, Manglio Rizzo, Guillermo Mazzolini, Juan I. Pascual, María Pilar Andueza, Jose Luis Perez-Gracia, and Ignacio Melero

CANCER THERAPY: PRECLINICAL

- 5708** **Activating and Propagating Polyclonal Gamma Delta T Cells with Broad Specificity for Malignancies**
Drew C. Deniger, Sourindra N. Maiti, Tiejuan Mi, Kirsten C. Switzer, Vijaya Ramachandran, Lenka V. Hurton, Sonny Ang, Simon Olivares, Brian A. Rabinovich, M. Helen Huls, Dean A. Lee, Robert C. Bast Jr, Richard E. Champlin, and Laurence J.N. Cooper
See related commentary, p. 5573

- 5720** **Neuroblastoma Killing Properties of V δ 2 and V δ 2-Negative $\gamma\delta$ T Cells Following Expansion by Artificial Antigen-Presenting Cells**
Jonathan P.H. Fisher, Mengyong Yan, Jennifer Heuijers, Lisa Carter, Ayda Abolhassani, Jennifer Frosch, Rebecca Wallace, Barry Flutter, Anna Capsomidis, Mike Hubank, Nigel Klein, Robin Callard, Kenth Gustafsson, and John Anderson
See related commentary, p. 5573

- 5733** **Human Anaplastic Thyroid Carcinoma Cells Are Sensitive to NK Cell-Mediated Lysis via ULBP2/5/6 and Chemoattract NK Cells**
Erik Wennerberg, Aline Pfefferle, Lars Ekblad, Yuya Yoshimoto, Veronika Kremer, Vitaliy O Kaminskyy, C Christofer Juhlin, Anders Höög, Inger Bodin, Vitalijs Svjatocha, Catharina Larsson, Jan Zedenius, Johan Wennerberg, and Andreas Lundqvist

- 5745** **Ponatinib Inhibits Polyclonal Drug-Resistant KIT Oncoproteins and Shows Therapeutic Potential in Heavily Pretreated Gastrointestinal Stromal Tumor (GIST) Patients**
 Andrew P. Garner, Joseph M. Gozgit, Rana Anjum, Sadanand Vodala, Alexa Schrock, Tianjun Zhou, Cesar Serrano, Grant Eilers, Meijun Zhu, Julia Ketzner, Scott Wardwell, Yaoyu Ning, Youngchul Song, Anna Kohlmann, Frank Wang, Tim Clackson, Michael C. Heinrich, Jonathan A. Fletcher, Sebastian Bauer, and Victor M. Rivera

- 5756** **Dual mTORC1/2 Blockade Inhibits Glioblastoma Brain Tumor Initiating Cells *In Vitro* and *In Vivo* and Synergizes with Temozolomide to Increase Orthotopic Xenograft Survival**
H. Artee Luchman, Owen D.M. Stechishin, Stephanie A. Nguyen, Xueqing Q. Lun, J. Gregory Cairncross, and Samuel Weiss

- 5768** **STAT3 Mediates Regorafenib-Induced Apoptosis in Hepatocellular Carcinoma**
Wei-Tien Tai, Pei-Yi Chu, Chung-Wai Shiau, Yao-Li Chen, Yong-Shi Li, Man-Hsin Hung, Li-Ju Chen, Pei-Lung Chen, Jung-Chen Su, Ping-Yi Lin, Hui-Chuan Yu, and Kuen-Feng Chen

BIOLOGY OF HUMAN TUMORS

- 5777** **Lung Squamous Cell Carcinomas with Basaloid Histology Represent a Specific Molecular Entity**
Christian Brambilla, Julien Laffaire, Sylvie Lantuejoul, Denis Moro-Sibilot, Hélène Mignotte, François Arbib, Anne-Claire Toffart, Fabien Petel, Pierre Hainaut, Sophie Rousseaux, Saadi Khochbin, Aurélien de Reyniès, and Elisabeth Brambilla

Table of Contents

- 5787** Validation of Biomarkers That Complement CA19.9 in Detecting Early Pancreatic Cancer
Alison Chan, Ioannis Prassas, Apostolos Dimitromanolakis, Randall E. Brand, Stefano Serra, Eleftherios P. Diamandis, and Ivan M. Blasutig
- 5796** A HGF/cMET Autocrine Loop Is Operative in Multiple Myeloma Bone Marrow Endothelial Cells and May Represent a Novel Therapeutic Target
 Arianna Ferrucci, Michele Moschetta, Maria Antonia Frassanito, Simona Berardi, Ivana Catacchio, Roberto Ria, Vito Racanelli, Antonella Caivano, Antonio Giovanni Solimando, Daniele Vergara, Michele Maffia, Dominga Latorre, Antonia Rizzello, Alfredo Zito, Paolo Ditonno, Eugenio Maiorano, Domenico Ribatti, and Angelo Vacca
- 5808** Tumor-Suppressive miR148a Is Silenced by CpG Island Hypermethylation in *IDH1*-Mutant Gliomas
Sichen Li, Reshmi Chowdhury, Fei Liu, Arthur P. Chou, Tie Li, Reema R. Mody, Jerry J. Lou, Weidong Chen, Jean Reiss, Horacio Soto, Robert Prins, Linda M. Liau, Paul S. Mischel, Phioanh L. Nghiemphu, William H. Yong, Timothy F. Cloughesy, and Albert Lai
- 5823** *PIK3CA* Mutational Status in Circulating Tumor Cells Can Change During Disease Recurrence or Progression in Patients with Breast Cancer
Athina Markou, Sofia Farkona, Christina Schiza, Tonia Efstathiou, Sophia Kounelis, Nikos Malamos, Vassilis Georgoulas, and Evi Lianidou
- 5835** LIM and SH3 Protein 1 Induces TGF β -Mediated Epithelial–Mesenchymal Transition in Human Colorectal Cancer by Regulating S100A4 Expression
 Hui Wang, Jiaolong Shi, Yuhao Luo, Qing Liao, Ya Niu, Feifei Zhang, Ziyun Shao, Yanqing Ding, and Liang Zhao
- 5848** The Renin–Angiotensin System Mediates EGF Receptor–Vitamin D Receptor Cross-Talk in Colitis-Associated Colon Cancer
Urszula Dougherty, Reba Mustafi, Farhana Sadiq, Anas Almoghrabi, Devkumar Mustafi, Maggi Kreisheh, Sumana Sundaramurthy, Weicheng Liu, Vani J. Konda, Joel Pekow, Sharad Khare, John Hart, Loren Joseph, Alice Wyrwicz, Gregory S. Karczmar, Yan Chun Li, and Marc Bissonnette


 AC icon indicates Author Choice

 CME icon indicates that this article is available for continuing medical education credit at <http://cme.aacrjournals.org>

For more information please visit www.aacrjournals.org

ABOUT THE COVER

The cover shows that the morphology of SW480 colorectal cancer cells in response to the treatment with TGF β for 48 hours have migrated through 8 μ m-diameter pores in a Transwell assay. Cells have been stained with Giemsa (magnification \times 400). For details, see the article by Wang and colleagues on page 5835 of this issue.



Clinical Cancer Research

20 (22)

Clin Cancer Res 2014;20:5571-5859.

Updated version Access the most recent version of this article at:
<http://clincancerres.aacrjournals.org/content/20/22>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://clincancerres.aacrjournals.org/content/20/22>. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.